Elezanumab
Sponsors
AbbVie Deutschland GmbH & Co. KG, AbbVie
Conditions
Acute Ischemic StrokeAcute Spinal Cord Injury (SCI)Acute Traumatic Cervical Spinal Cord InjuryMultiple Sclerosis (MS)Spinal Cord Injury (SCI)
Phase 2
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
CompletedNCT03737812
Start: 2019-02-27End: 2021-08-30Updated: 2023-12-21
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
CompletedNCT03737851
Start: 2018-12-11End: 2021-09-09Updated: 2023-12-22
Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)
CompletedNCT04295538
Start: 2020-09-06End: 2026-01-26Updated: 2026-02-11
A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
CompletedNCT04309474
Start: 2020-11-09End: 2024-12-23Updated: 2025-12-22
A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury
CompletedCTIS2023-505125-14-00
Start: 2020-07-24End: 2026-01-21Target: 8Updated: 2023-11-08